When is crossover desirable in cancer drug trials and when is it problematic?
Journal List Ann Oncol PMC5961160 Ann Oncol. 2018 May; 29(5): 1079–1081. The use of crossover, as a design feature of randomized trials, is common, with…
Related Articles
DanGer Shock – First Positive RCT of Impella – Cardiogenic Shock – A critical appraisal
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 450+ Peer Reviewed papers,…
Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? – PubMed
The phase 3 PROfound trial led to the recent approval of the PARP inhibitor olaparib for men with metastatic castration-resistant prostate cancer and mutations in…
The US FDA’s cancer drug approval process is broken and need audit
Cancer is deadly, but 68% of the drugs approved by FDA have no evidence they increase survival!
Opinion | Op-Ed: Public Schools Should (Almost Always) Stay Open
It does the least harm to kids and adults
Cancer Drugs Approved on the Basis of a Surrogate End Point
This review of approvals of cancer drugs based on a surrogate end point by the US Food and Drug Administration assesses the postmarketing findings for…
An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
Cancer Medicine is an open access, broad-scope oncology journal covering clinical cancer research, cancer biology, cancer prevention, & bioinformatics.